Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials
Journal
The lancet. Gastroenterology & hepatology
Journal Volume
8
Journal Issue
7
Pages
632-634
Date Issued
2023-07
Author(s)
Chen, Po-Yueh
Bair, Ming-Jong
Yang, Tsung-Hua
Lee, Ji-Yuh
Yu, Chien-Chun
Kuo, Chia-Chi
Chiu, Min-Chin
Chou, Chu-Kuang
Chen, Chi-Yi
Tsai, Min-Horn
Hsu, Yao-Chun
Luo, Jiing-Chyuan
El-Omar, Emad M
Abstract
Helicobacter pylori infection is an important causal factor of gastric cancer and peptic ulcer disease and is associated with immune thrombocytopenic purpura and functional dyspepsia. In H pylori strains, point mutations in the 23S rRNA and gyrA genes are associated with clarithromycin resistance and levofloxacin resistance, respectively. Whether the efficacy of molecular testing-guided therapy is non-inferior to that of susceptibility testing-guided therapy for H pylori eradication is unclear. Therefore, we aimed to compare the efficacy and safety of molecular testing-guided therapy and traditional culture-based susceptibility testing-guided therapy in first-line and third-line treatment of H pylori infection.
Type
journal article